Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

676 recalls · Class II, newest first

Class II · Moderate risk

Entecavir Tablets

Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 68382-921-06 D-0002-2026
Class II · Moderate risk

Entecavir Tablets

Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 68382-920-06 D-0001-2026
Class II · Moderate risk

Fentanyl citrate

CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.

Ongoing cGMP deviation Park Avenue Compounding NDC 83863-4272-1 D-0178-2026
Class II · Moderate risk

Azelaic Acid Gel

CGMP Deviations: Market complaints received for gritty texture (grainy)

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-626-52 D-0662-2025
Class II · Moderate risk

Levothyroxine Sodium Tablets

Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

Ongoing Wrong potency / content Accord Healthcare, INC. NDC 16729-450-15 D-0006-2026
Class II · Moderate risk

edunn clarity

Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.

Ongoing Chemical / undeclared Private Label Skin Care Inc. D-0668-2025
Class II · Moderate risk

Micronized BPO Gel Cleanser 10%

Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.

Ongoing Chemical / undeclared Private Label Skin Care Inc. D-0667-2025
Class II · Moderate risk

mel rx Skin

Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.

Ongoing Chemical / undeclared Private Label Skin Care Inc. D-0666-2025
Class II · Moderate risk

Skin MD by Dr Monika Kiripolsky

Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.

Ongoing Chemical / undeclared Private Label Skin Care Inc. D-0664-2025
Class II · Moderate risk

Artisan of Skin

Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.

Ongoing Chemical / undeclared Private Label Skin Care Inc. D-0663-2025
Class II · Moderate risk

Major ChlorproMAZINE Hydrochloride Tablets

CGMP Deviations: Presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit

Ongoing Nitrosamine impurity The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7133-61 D-0013-2026
Class II · Moderate risk

Major ChlorproMAZINE Hydrochloride Tablets

CGMP Deviations: Presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit

Ongoing Nitrosamine impurity The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7132-61 D-0012-2026
Class II · Moderate risk

Major ChlorproMAZINE Hydrochloride Tablets

CGMP Deviations: Presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit

Ongoing Nitrosamine impurity The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7131-61 D-0011-2026

Recalls by year